Q-omics provides the consensus-scored GPR146 profile across patient tissues and cancer cell-line models. GPR146 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GPR146 is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, GPR146 RNA expression shows 19,053 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, LUAD, and THYM as cancer lineages where GPR146 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR146 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR146 survival associations across molecular data types. GPR146 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR146 RNA expression–survival associations across cancer types. High GPR146 expression shows unfavorable associations in BLCA, COAD, OV and KIRP, but favorable associations in KIRC and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for GPR146 RNA expression.
This table summarizes GPR146 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for GPR146. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR146 shows lower tumor expression in LUAD, THCA, KIRP, LUSC and BLCA and higher tumor expression in KIRC. The LUAD box plot shows higher GPR146 RNA expression in normal versus tumor tissue (log2 FC = −2.223, t-test p < 0.001).
This table shows molecular features associated with GPR146 in patient tissues and cancer cell lines. In patient samples, GPR146 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR146 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
